Multiple sclerosis trials in Greece
10 of 13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Athens, Chaïdári, Cholargos, Larissa, Thessaloniki
- Age
- 18 years to 60 years
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - Phase 3Taking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Athens, Chaïdári, Cholargos, Larissa
- Age
- 18 years to 60 years
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - Phase 3Taking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Ioannina, Thessaloniki
- Age
- 18 years to 64 years
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - Phase 3Taking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Athens, Larissa, Thessaloniki
- Age
- 40 years to 70 years
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - Phase 1Taking peopleSafety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for MS
- Where
- Athens
- People
- 15 worldwide
- Run by
- The Foundation for Orthopaedics and Regenerative Medicine
See details and how to joinNCT05003388 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Athens, Chaïdári, Ioannina, Larissa, Thessaloniki
- Age
- 18 years to 65 years
- People
- 1,275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - Phase 3Taking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Athens, Ioannina, Larissa, Thessaloniki
- Age
- 18 years to 60 years
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - Phase 2Taking peopleA Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
- Where
- Chaïdári, Larissa
- Age
- 18 years to 64 years
- People
- 93 worldwide
- Run by
- Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00 - Phase 3Taking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Athens, Chaïdári, Cholargos, Ioannina, Larissa, Thessaloniki
- Age
- 18 years and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - Phase 4Not yet taking people in GreeceEffects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.
- Where
- Thessaloniki
- Age
- 18 years to 64 years
- People
- 30
- Run by
- Aristotle University Of Thessaloniki
See details and how to join2025-521910-24-00 · EU 2025-521910-24-00